Adma Biologics (ADMA) Common Equity (2011 - 2025)

Adma Biologics has reported Common Equity for 15 years, with the latest figure at $477.3 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity rose 36.76% year-over-year to $477.3 million; the trailing twelve-month figure through Dec 2025 stood at $477.3 million (up 36.76% YoY), and the FY2025 full-year result was $477.3 million, up 36.76% from the prior year.
• Common Equity for Q4 2025 stood at $477.3 million, up from $431.2 million in the prior quarter.
• The five-year high for Common Equity was $477.3 million in Q4 2025, with the low at $100.4 million in Q3 2022.
• Historically, Common Equity has averaged $207.2 million across 5 years, with a median of $149.1 million in 2023.
• Annual changes were most pronounced in 2023 — Common Equity declined 11.03% — and 2024, when it soared 158.14%.
• Adma Biologics' Common Equity stood at $141.2 million in 2021, then rose by 7.65% to $152.0 million in 2022, then retreated by 11.03% to $135.2 million in 2023, then soared by 158.14% to $349.0 million in 2024, then jumped by 36.76% to $477.3 million in 2025.
• The last three Common Equity figures came in at $477.3 million (Q4 2025), $431.2 million (Q3 2025), and $398.3 million (Q2 2025), per Business Quant data.